Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1/2 4Phase 1 4Phase NA 1Phase 4 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 2Recurrence 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Lymphoid 1Leukemia 1Hematologic Neoplasms 1

Interventions

ceftolozane, tazobactam drug combination 2Meropenem 2Itraconazole 2rasburicase 1pegylated granulocyte colony-stimulating factor 1pegaspargase 1fludarabine phosphate 1fludarabine 1eltrombopag 1drotrecogin alfa activated 1dexamethasone 21-phosphate 1Voriconazole 1Vancomycin 1Uric Acid 1Urate Oxidase 1Tropisetron 1Teicoplanin 1Solutions 1Ribavirin 1Pegloticase 1Oxidoreductases 1Ofloxacin 1Micafungin 1Metronidazole 1Imatinib Mesylate 1Hydromorphone 1Human Papillomavirus Recombinant Vaccine nonavalent 1Dexamethasone 1Dasatinib 1Ciprofloxacin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Hematologic Neoplasms × Busulfan × Clear all
NCT00361140 2017-03-03

Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

H. Lee Moffitt Cancer Center and Research Institute

Phase 4 Completed
72 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoid, Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡